What does the company have to do with it?? They would be buying the drug. They don't need any part of Amarin. I don't see how that reduces the multiple. If anything, it should increase it because it isn't coming with overhead.
So, if we agree that there is NO potential upside to Vascpa - no new indications, no new formulation, no combo-drugs, etc. then MAYBE 2x is fair. But there's a LOT of upside.
News 
Market Data 
Discover 
